J. Andrew Livingston,Jean-Yves Blay,Jonathan Trent,Claudia Valverde,Mark Agulnik,Mrinal Gounder,Axel Le Cesne,Meredith McKean,Michael J. Wagner,Silvia Stacchiotti,Samuel Agresta,Alfonso Quintás-Cardama,Sarah A. Reilly,Kathleen Healy,Denice Hickman,Tina Zhao,Alex Ballesteros-Perez,Alexis Khalil,Michael P. Collins,Jessica Piel,Kim Horrigan,Ariel Lefkovith,Scott Innis,Alexander J. Lazar,Gregory M. Cote,Andrew J. Wagner

Abstract:Purpose: FHD-609, a potent, selective, heterobifunctional degrader of bromodomain-containing protein 9 (BRD9), was evaluated for treatment of patients with advanced synovial sarcoma (SS) or SMARCB1-deficient tumors. Patients and methods: In this multinational, open-label, phase 1 study (NCT04965753), patients received FHD609 intravenously at escalating doses either twice weekly (BIW) (5 to 80 mg; n=40) or once weekly (QW) (40 to 120 mg; n=15). Results: Fifty-five patients received FHD-609 for a median of 43 days. The maximum tolerated doses (MTDs) were 40 mg BIW and the equivalent weekly dose, 80 mg QW. Dose-limiting toxicities of QTc prolongation and syncope were observed at 40 and 60 mg BIW. Treatment-related adverse events were predominantly Grade 1-2 in severity, most commonly dysgeusia (40%), dry mouth (29.1%), fatigue (27.3%), and anemia (25.5%). Eleven (20%) patients had treatment-emergent QTcF prolongation preceded by T-wave inversions; 21 (38.2%) patients had T-wave inversions without further cardiac events or ECG abnormalities. FHD-609 showed dose-dependent increases in pharmacokinetic exposure, with no substantial accumulation. Extensive BRD9 degradation in tumor tissue corresponded to downregulation of cancer cell proliferation gene sets. One (2%) patient achieved a partial response; 8 (15%) patients achieved stable disease, which lasted longer than 6 months in 2 patients. Conclusions: FHD-609 showed dose-dependent increases in systemic FHD-609 exposure and pharmacodynamic response profiles. The MTDs were identified (40 mg BIW/80 mg QW) and preliminary clinical activity was observed. Future studies of BRD9 degraders will require strict cardiac monitoring given the QTc prolongation observed in this study.

Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9

Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors

Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity.

Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia

Design and synthesis of novel bispecific molecules for inducing BRD4 protein degradation

CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.

Discovery of Novel Small Molecule Induced Selective Degradation of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD4 and BRD2 with Cellular Potencies.

Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer

Development of Small-Molecule BRD4 Degraders Based on Pyrrolopyridone Derivative

Discovery of Selective CDK9 Degraders with Enhancing Antiproliferative Activity Through PROTAC Conversion

Design, Synthesis, and Biological Evaluation of BRD4 Degraders.

Design, synthesis, and biological evaluation of BRD4 degrader

Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity

Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression

Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide.

Identification of Highly Efficacious PROTACs Targeting BRD4 Against Acute Myeloid Leukemia: Design, Synthesis, and Biological Evaluations

A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity.

Design and Synthesis of Proteolysis Targeting Chimeras for Inducing BRD4 Protein Degradation

Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation

A Phase 1 Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients With Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors